REPORT SCOPE
INTRODUCTION
BCC's goal for this study was to determine the current status of emerging commercial epigenomics technologies and products and assess their worldwide growth potential over a 5-year period from 2007 to 2012. We were particularly interested in characterizing the epigenomic research tools market, a key enabling technology for other epigenomics markets. Of particular interest were the larger markets for DNA methylation-based diagnostics and epigenetic drugs for cancer.
Our key objective was to present a comprehensive discussion of where the state-of-the-art is in epigenomics technologies and the current and future commercial potential for the key market segments.
SCOPE OF STUDY
This report contains:
The major epigenomics technologies and developments that are likely to become commercialized within the next five years Provides detailed market information for the global epigenomics market including historical data, current information, and projections to 2012 Offers a focus on particular applications of epigenomics, including research tools, diagnostics, drugs, and cloning/tissue engineering Discusses the market in terms of important medical applications such as biomarkers, cancer therapy, and reproductive technology Offers a detailed review of important patents and technologies Profiles the most competitive businesses in the industry.
METHODOLOGY
BCC presents an analysis of each of the three key market segments that will be commercially important during the next 5 years: research tools, cancer diagnostics, and cancer therapeutics.
Based on our analysis, we analyze the potential applications of epigenomics in each of the major market segments, and forecast sales revenues for 2007 through 2012.
For research tools, the study presents a forecast from 2007 through 2012 for each of the important products and technologies. For cancer diagnostics, the report forecasts from 2007 through 2012 the demand for epigenetic-based test kits by cancer and disease type. Finally, this study forecasts from 2007 through 2012 the market for epigenetic drugs by cancer type.
INFORMATION SOURCES
BCC surveyed life science companies and research institutions to obtain data for this study. Included were research tools firms, diagnostics firms, drug firms, epigenetic biotechnology companies, and leading epigenomic research institutions. We also spoke with users of in vitro personalized medicine devices. In addition, we compiled data from secondary sources including industry, trade, and government.
ANALYST CREDENTIALS
John Bergin has more than 20 years experience at both high-technolory Fortune 500 companies and start-up technology firms. His experience includes strategy development, commercialization of high-technology products, and international expansion in various industries, including biotechnology, bioseparations, analytical separation, advanced materials, and metals separations. He holds a Master of Science Degree in Biotechnology and a Bachelor of Science Degree in Chemistry.
